ZMYND10 Antibody (Center) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | O75800 |
---|---|
Clone Names | 81201111 |
Gene ID | 51364 |
---|---|
Other Names | Zinc finger MYND domain-containing protein 10, Protein BLu, ZMYND10, BLU |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | ZMYND10 (HGNC:19412) |
---|---|
Function | Plays a role in axonemal structure organization and motility (PubMed:23891469, PubMed:23891471). Involved in axonemal pre-assembly of inner and outer dynein arms (IDA and ODA, respectively) for proper axoneme building for cilia motility (By similarity). May act by indirectly regulating transcription of dynein proteins (By similarity). |
Cellular Location | Cytoplasm {ECO:0000250|UniProtKB:Q6AXZ5}. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriolar satellite {ECO:0000250|UniProtKB:Q6AXZ5}. Apical cell membrane {ECO:0000250|UniProtKB:Q99ML0}. Dynein axonemal particle {ECO:0000250|UniProtKB:Q5FWU8} |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
BLU is a candidate tumor suppressor gene, that spans 4.5 kb on 3p21.3. It encodes a 50 kd protein, which is commonly found in transcription repressors. It is suspected that BLU has a function in cell cycle progression. BLU is a stress-responsive gene regulated by E2F.12 It is commonly found to be downregulated in non-small cell lung cancer, esophagus squamous cell carcinoma and nasopharyngeal carcinoma (NPC).
References
Shao, Y., et al. Cancer Invest. 28(6):642-648(2010)Lorente, A., et al. Brain Pathol. 19(2):279-292(2009)Muzny, D.M., et al. Nature 440(7088):1194-1198(2006)Marsit, C.J., et al. Int. J. Cancer 114(2):219-223(2005)Qiu, G.H., et al. Oncogene 23(27):4793-4806(2004)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.